Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 10/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 7/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | BCL6 | P41182 | 1/20 | 0.38 |
| ▸ | BCOR | Q6W2J9 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3120881 | 0.86 | POLB (0.54) | POLBAKR1C3CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL1964392 | 0.84 | AKR1C3 (0.55) | POLBAKR1C3CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL2924505 | 0.82 | POLB (0.58) | POLBAKR1C3CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL1968399 | 0.80 | POLB (0.58) | POLBAKR1C3CSNK2A1NPC1RAB9A | |
| SCHEMBL1967311 | 0.79 | AKR1C3 (0.50) | POLBAKR1C3CSNK2A1NPC1RAB9A | |
| SCHEMBL16318709 | 0.79 | AKR1C3 (0.50) | POLBAKR1C3 | |
| SCHEMBL3132437 | 0.79 | CLCN2 (0.46) | POLBAKR1C3ALDH1A1MEN1KMT2A | |
| SCHEMBL1966454 | 0.78 | AKR1C3 (0.54) | POLBAKR1C3CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL3128528 | 0.76 | AKR1C3 (0.52) | POLBAKR1C3CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL2929452 | 0.76 | AKR1C3 (0.71) | POLBAKR1C3CSNK2A1CSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040565-B2 | 1H-benzimidazole-5-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2015-05-26 | — | — | US | disclosed |
| US-20120122930-A1 | 1H-Benzimidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-17 | — | — | US | disclosed |
| WO-2010034797-A1 | 1H-BENZIMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122930-A1 | 1H-Benzimidazole-5-Carboxamides As Anti-Inflammatory Agents | MAPRE2, MAPRE1, MAP4 | POLB 3320/4885AKR1C3 1829/4885CSNK2A1 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.